Cargando…
Virotherapy Using Myxoma Virus Prevents Lethal Graft-versus-Host Disease following Xeno-Transplantation with Primary Human Hematopoietic Stem Cells
Graft-versus-host disease (GVHD) is a potentially lethal clinical complication arising from the transfer of alloreactive T lymphocytes into immunocompromised recipients. Despite conventional methods of T cell depletion, GVHD remains a major challenge in allogeneic hematopoietic cell transplant. Here...
Autores principales: | Bartee, Eric, Meacham, Amy, Wise, Elizabeth, Cogle, Christopher R., McFadden, Grant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419197/ https://www.ncbi.nlm.nih.gov/pubmed/22905251 http://dx.doi.org/10.1371/journal.pone.0043298 |
Ejemplares similares
-
Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020) -
Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012) -
Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor
por: Lilly, Cameron L., et al.
Publicado: (2016) -
Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease
por: Villa, Nancy Y., et al.
Publicado: (2018) -
Myxoma Virus Targets Primary Human Leukemic Stem and Progenitor Cells While Sparing Normal Hematopoietic Stem and Progenitor Cells
por: Kim, Manbok, et al.
Publicado: (2009)